{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T08:46:18Z","timestamp":1773305178105,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clml.2024.05.015","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T02:09:04Z","timestamp":1716257344000},"page":"e366-e375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk of Secondary Malignancies After Multiple Myeloma: A Nationwide Case-Control Cohort Study"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7293-2101","authenticated-orcid":false,"given":"Heejoo","family":"Ko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9976-5120","authenticated-orcid":false,"given":"Seunghoon","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5438-7819","authenticated-orcid":false,"given":"Suein","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ja Min","family":"Byun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.05.015_bib0001","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.015_bib0002","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2024.05.015_bib0003","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/cncr.22850","article-title":"Epidemiology of multiple myeloma in Taiwan: increasing incidence for the past 25 years and higher prevalence of extramedullary myeloma in patients younger than 55 years","volume":"110","author":"Huang","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2024.05.015_bib0004","volume":"7","author":"Khuhaprema","year":"2013"},{"key":"10.1016\/j.clml.2024.05.015_bib0005","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12185-010-0617-6","article-title":"Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party","volume":"92","author":"Lee","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2024.05.015_bib0006","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2006.09.0100","article-title":"Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003","volume":"25","author":"Kristinsson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.05.015_bib0007","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1200\/JCO.2009.25.4177","article-title":"Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study","volume":"28","author":"Turesson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.05.015_bib0008","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood-2011-12-381426","article-title":"Second malignancies after multiple myeloma: from 1960s to 2010s","volume":"119","author":"Thomas","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.015_bib0009","first-page":"1","article-title":"Risk of second primary cancers in multiple myeloma survivors in German and Swedish cancer registries","volume":"6","author":"Chen","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.clml.2024.05.015_bib0010","doi-asserted-by":"crossref","first-page":"e68041","DOI":"10.1371\/journal.pone.0068041","article-title":"Time trend of multiple myeloma and associated secondary primary malignancies in Asian patients: a Taiwan population\u2013based study","volume":"8","author":"Tzeng","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2024.05.015_bib0011","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1038\/bcj.2014.63","article-title":"Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups","volume":"4","author":"Ailawadhi","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2024.05.015_bib0012","first-page":"4507","article-title":"Increased incidence of a second lymphoproliferative malignancy in patients with multiple myeloma\u2014a SEER based study","volume":"32","author":"Chakraborty","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clml.2024.05.015_bib0013","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ajh.23731","article-title":"Clinical profiles of multiple myeloma in Asia\u2014an Asian Myeloma Network study","volume":"89","author":"Kim","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2024.05.015_bib0014","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma","volume":"134","author":"Rosi\u00f1ol","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.015_bib0015","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.5045\/br.2020.S007","article-title":"Frontline therapy for newly diagnosed patients with multiple myeloma","volume":"55","author":"Jung","year":"2020","journal-title":"Blood Res"},{"key":"10.1016\/j.clml.2024.05.015_bib0016","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.05.015_bib0017","doi-asserted-by":"crossref","first-page":"83","DOI":"10.5045\/br.2023.2023005","article-title":"Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study","volume":"58","author":"Byun","year":"2023","journal-title":"Blood Res"},{"key":"10.1016\/j.clml.2024.05.015_bib0018","doi-asserted-by":"crossref","first-page":"395","DOI":"10.4093\/dmj.2014.38.5.395","article-title":"Background and data configuration process of a nationwide population-based study using the korean national health insurance system","volume":"38","author":"Song","year":"2014","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.clml.2024.05.015_bib0019","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/19371910903070333","article-title":"Introduction: health of the health care system in Korea","volume":"25","author":"Kim","year":"2010","journal-title":"Soc Work Public Health"},{"key":"10.1016\/j.clml.2024.05.015_bib0020","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/ijc.34115","article-title":"Risk of secondary nonhematologic malignancies after allogeneic stem cell transplantation: a nationwide case-control cohort study","volume":"151","author":"Park","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2024.05.015_bib0021","doi-asserted-by":"crossref","first-page":"15265","DOI":"10.1038\/s41598-020-71208-2","article-title":"Pre-transplant depression decreased overall survival of patients receiving allogeneic hematopoietic stem cell transplantation: a nationwide cohort study","volume":"10","author":"Wang","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.clml.2024.05.015_bib0022","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2024.05.015_bib0023","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.3324\/haematol.2015.134049","article-title":"Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study","volume":"101","author":"Jonsdottir","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2024.05.015_bib0024","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.3109\/10428194.2014.970543","article-title":"Therapy-related myelodysplastic syndrome\/acute leukemia after multiple myeloma in the era of novel agents","volume":"56","author":"Gertz","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2024.05.015_bib0025","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/DSS.0000000000003478","article-title":"Increased incidence of melanoma in patients with multiple myeloma: a cross-sectional analysis of the surveillance, epidemiology, and end results database","volume":"48","author":"Singh","year":"2022","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.clml.2024.05.015_bib0026","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2024.05.015_bib0027","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2024.05.015_bib0028","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1182\/blood.V122.21.3100.3100","article-title":"Second malignant neoplasms following multiple myeloma: a cohort study on 744 patients treated 1997-2011","volume":"122","author":"Kleber","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.015_bib0029","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.beha.2019.02.003","article-title":"Therapy-related myeloid neoplasms after treatment for plasma-cell disorders","volume":"32","author":"Chung","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clml.2024.05.015_bib0030","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1182\/blood-2019-127469","article-title":"-Myeloma XI trial for newly diagnosed multiple myeloma (NDMM); long term second primary malignancy (SPM) incidence in the context of lenalidomide maintenance","volume":"134","author":"Jones","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.015_bib0031","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1200\/JCO.1992.10.2.334","article-title":"Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials","volume":"10","author":"Gregory","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.05.015_bib0032","first-page":"101","article-title":"Multiple myeloma: diagnosis and treatment","volume":"91","author":"Rajkumar","year":"2016"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502400199X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502400199X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T15:10:38Z","timestamp":1729696238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502400199X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S215226502400199X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.05.015","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Secondary Malignancies After Multiple Myeloma: A Nationwide Case-Control Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}